AIC
GALT icon

Archer Investment Corporation’s Galectin Therapeutics GALT Stock Holding History

Archer Investment Corporation’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37.7K Buy
13,501
+608
+5% +$1.85K 0.01% 574
2025
Q4 		$53.6K Buy
12,893
+1,893
+17% +$9.97K 0.01% 465
2025
Q3 		$46.6K Buy
+11,000
New +$41.4K 0.01% 487

Other funds holding GALT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Archer Investment Corporation's GALT Position: Q1 2026 in Review

Archer Investment Corporation increased its Galectin Therapeutics (GALT) stake by 4.7% in Q1 2026, buying an estimated $1.85K and bringing the position to 13,501 shares worth $37.7K. The position accounts for 0.01% of the portfolio, ranked #574.

Archer Investment Corporation first reported a position in GALT in Q3 2025 and has held it in 3 quarters since. The position peaked at $53.6K in Q4 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

  • Archer Investment Corporation held 13,501 shares of Galectin Therapeutics worth $37.7K as of Q1 2026.
  • Archer Investment Corporation bought 608 Galectin Therapeutics shares in Q1 2026, an estimated $1.85K.
  • Galectin Therapeutics made up 0.01% of Archer Investment Corporation's portfolio in Q1 2026, its #574 holding.
  • Archer Investment Corporation first reported a position in Galectin Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Archer Investment Corporation's Galectin Therapeutics position peaked at $53.6K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on Archer Investment Corporation's 13F filing for Q1 2026, filed 4 May 2026.